

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
FDA APPROVAL FOR PIVOTAL TRIAL OF LUX-VALVE PLUS

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that LuX-Valve Plus, the transcatheter tricuspid valve replacement system independently developed by the Company, has officially obtained unconditional investigational device exemption (“**IDE**”) approval from the U.S. Food and Drug Administration (the “**FDA**”) for its pivotal clinical trial. This marks a significant breakthrough in the U.S. registration progress of LuX-Valve Plus and the Group’s global strategy.

LuX-Valve Plus has demonstrated excellent performance in its registration clinical trials conducted in China, Europe, and other countries and regions, the clinical data of the Early Feasibility Study (the “**EFS**”) of LuX-Valve Plus conducted in the U.S. further validates the advantages of the device design as well as its safety and effectiveness in clinical application. The EFS of LuX-Valve Plus has obtained the approval of the Centers for Medicare & Medicaid Services of the U.S. (the “**CMS**”) medical insurance, covering the costs of the devices required for the study and the relevant expenses. The aforesaid progress has laid a solid foundation for the IDE approval of the pivotal clinical trial and the subsequent commencement of the pivotal clinical trial.

The Company will immediately and proactively advance the enrollment for the pivotal clinical trial of LuX-Valve Plus, striving to secure the FDA approval for the product as soon as possible, and promote the commercialization of LuX-Valve Plus in the U.S. and other regions worldwide, delivering the earlier benefit to the broad global patient population suffering from tricuspid regurgitation.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately successfully market and/or commercialize LuX-Valve Plus. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, February 6, 2026

As at the date of this announcement, the executive Director of the Company is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.